- ISIN
- US45256X1037
- CUSIP
- 45256X103
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 28, 2015
Highlights
- Market Cap
- $7.51B
- Enterprise Value
- $7.35B
- EPS (TTM)
- -$0.87
- Total Revenue (TTM)
- $140.98M
- Gross Profit (TTM)
- $132.23M
- EBITDA (TTM)
- -$196.14M
- Year Range
- $1.95 - $12.43
- Target Price
- $13.50
- ROA (TTM)
- -132.15%
- ROE (TTM)
- 98.32%
- Avg. Volume (1M)
- 10M
- Avg. Volume Value (1M)
- $77.42M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
IBRX Performance Chart
ImmunityBio, Inc. (IBRX) is up 262.1% since the beginning of the year. At $7 per share, IBRX is trading 42.3% below its 52-week high of $12. Investors who bought $1,000 worth of IBRX shares 5 years ago would now be looking at an investment worth $654.
Loading charts...
Compare this symbol against anything
Returns By Period
ImmunityBio, Inc. (IBRX) has returned 262.12% so far this year and 202.53% over the past 12 months. Over the last ten years, IBRX has returned -0.45% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
ImmunityBio, Inc.
- 1D
- -3.76%
- 1M
- -24.05%
- 6M
- 14.72%
- YTD
- 262.12%
- 1Y
- 202.53%
- 3Y*
- 52.04%
- 5Y*
- -8.14%
- 10Y*
- -0.45%
- ALL TIME*
- -13.85%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
IBRX Monthly Returns History
Based on dividend-adjusted daily data since Jul 28, 2015, IBRX's average daily return is +0.17%, while the average monthly return is +3.31%. At this rate, an investment would double in approximately 1.8 years.
Historically, 41% of months were positive and 59% were negative. The best month was Jan 2026 with a return of +215.7%, while the worst month was Dec 2024 at -49.2%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 5 months.
On a daily basis, IBRX closed higher 45% of trading days. The best single day was Jan 13, 2020 with a return of +91.0%, while the worst single day was May 11, 2023 at -55.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 215.66% | 56.48% | -21.57% | -7.43% | 5.92% | 16.42% | -18.10% | 262.12% | |||||
| 2025 | 34.77% | -4.64% | -8.51% | -16.61% | 5.98% | -0.75% | -6.82% | -4.88% | 5.13% | -2.44% | -1.67% | -16.10% | -22.66% |
| 2024 | -33.07% | 40.77% | 13.53% | 48.79% | -19.65% | -1.56% | -18.51% | -23.30% | -5.82% | 40.05% | -3.26% | -49.21% | -49.00% |
| 2023 | -25.05% | -35.79% | -25.41% | 53.85% | -1.79% | 1.09% | -20.86% | -26.82% | 4.97% | 85.80% | 17.20% | 36.41% | -0.99% |
| 2022 | -4.28% | 17.53% | -17.98% | -35.29% | 3.58% | -1.06% | 4.57% | 2.83% | 24.25% | 10.66% | 0.18% | -7.99% | -16.61% |
| 2021 | 41.60% | 72.24% | -26.98% | -25.23% | -1.13% | -18.63% | -23.25% | 3.83% | -14.41% | -19.61% | -0.51% | -21.95% | -54.39% |
Benchmark Metrics
ImmunityBio, Inc. has an annualized alpha of 20.48%, beta of 1.79, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since July 28, 2015.
- This stock participated in 182.27% of S&P 500 Index downside but only 77.59% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 20.48%
- Beta
- 1.79
- R²
- 0.09
- Upside Capture
- 77.59%
- Downside Capture
- 182.27%
Return for Risk
Risk / Return Rank
IBRX ranks 90 for risk / return — above 90% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for ImmunityBio, Inc. (IBRX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| IBRX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.41 | ||
| Sortino ratioReturn per unit of downside risk | +0.93 | ||
| Omega ratioGain probability vs. loss probability | 1.35 | 1.25 | +0.09 |
| Calmar ratioReturn relative to maximum drawdown | 4.55 | 2.00 | +2.55 |
| Martin ratioReturn relative to average drawdown | 7.64 | 8.49 | -0.85 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the ImmunityBio, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ImmunityBio, Inc. was 97.30%, occurring on Jun 10, 2019. Recovery took 428 trading sessions.
The current ImmunityBio, Inc. drawdown is 83.03%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-97.30%Jun 2019 | 3y 10mo | 1y 8mo | 5y 6moJul 2015 - Feb 2021 | — |
-97.03%Oct 2023 | 2y 7mo | — | 5y 5moFeb 2021 - now | — |
Drawdown Indicators
| IBRX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.30% | -56.78% | -40.52% |
Max Drawdown (1Y)Largest decline over 1 year | -42.34% | -9.10% | -33.24% |
Max Drawdown (3Y)Largest decline over 3 years | -79.34% | -18.90% | -60.44% |
Max Drawdown (5Y)Largest decline over 5 years | -89.36% | -25.43% | -63.93% |
Max Drawdown (10Y)Largest decline over 10 years | -97.03% | -33.92% | -63.11% |
Current DrawdownCurrent decline from peak | -83.03% | -1.58% | -81.45% |
Average DrawdownAverage peak-to-trough decline | -84.35% | -10.70% | -73.65% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 25.17% | 2.14% | +23.03% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of ImmunityBio, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how ImmunityBio, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for IBRX relative to other companies in the Biotechnology industry. Currently, IBRX has a P/S ratio of 50.2. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with IBRX
Add ImmunityBio, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with IBRX